2004

XVI International Congress of Eye Research

• DAY:
• Place：Sydney, Australia
• Calpain-specific proteolysis in monkey retina
• Emi Nakajima1,2, Michael A. Riviere2, Yoshiyuki Tamada1, Larry L. David2 Nakajima1, Mitsuyoshi Azuma1,2 and Thomas R. Shearer2
  1 Senju Pharmaceutical Co. Ltd., 2 Oregon Health & Science University

The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• ①Involvement of cyclooxygenase-2 in rat models of anterior ocular inflammation
  ②Involvement of Egr-1 in lens epithelial cell death induced by selenite
  ③Regeneration of Retinal Ganglion Cells Induced by suppression of Rho-Associated Protein Kinase
  ④Calpain-induced proteolysis in lens epithelial cell death during ovine inherited cataract
• ①M.Azuma1,　T.Oka1,　T.R. Shearer2
  　1Research Laboratories, Senju Pharmaceutical Co Ltd, Kobe, Japan; 2Department of Integrative Biosciences, Oregon Health & Science University, Portland, OR.
  ②T. Nakajima1,　P.B. Belusko1,　R. Walkup1,　M. Azuma1, T.R. Shearer2
  　1Research Laboratories, Senju Pharmaceutical Co Ltd, Kobe, Japan; 2Department of Integrative Biosciences, Oregon Health & Science University, Portland, OR.
  ③Y.Takayama1,　C.Fukiage1,　H.Tokushige1,　Y.Yoshida1,　M.Azuma1,　M.Uehata2
  　1Research Laboratories, Senju Pharmaceutical Co Ltd, Kobe, Japan; 2Discovery Technology Laboratory, Mitsubishi Pharma Corporation, Yokohama, Japan.
  ④L.J. G. Robertson1,　E.Nakajima2,　J.D. Morton1,　L.L. David3,　 T.R. Shearer3,　M.Azuma2
  　1Animal & Food Sciences Division, Lincoln University, Christchurch, New Zealand; 2Senju Pharmaceutical, Beaverton, OR; 3Integrative Biosciences, Oregon Health & Sciences University, Portland, OR.

() () () ()

5th International Symposium on Ocular Pharmacology and Therapeutics (5th ISOPT)

• DAY:
• Place：Monte Carlo, MONACO

・TAU-284
　Safety and efficacy of topical bepotastine besilate in conjunctival allergen challenge model
　T. Sekiya
・SJE-2079
　Safety and efficacy of topical difluprednate in patients with severe anterior uveitis
　T. Ogawa
・TimolastTM
　Ocular hypotensive effect of a new “once-daily” eye-drops formulation of 0.5％ timolol (TimolastTM) in comparison to TimoptolTM 0.5％ administered twice-daily : A 4-month multicenter cross-over clinical trial
　J. F. Rouland, ....

US-JAPAN Cooperative Cataract Research Group Meeting

• DAY:
• Place：Kona, Hawaii, USA
• The activation and regulation of lens-specific calpain Lp82 in rodent lens
• C. Fukiage,　M. Azuma and T.R. Shearer

new | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999